EBITDA Momentum in Focus as Zone IV Ramps, Deal Upside Looms
Aarti Industries reports Q2 FY-27 on Oct 30. Expect strong revenue momentum and margin accretion driven by Phase I Zone IV commissioning and operational leverage. Street consensus is bullish, but valuation debate centres on execution risk from ₹1,500 Cr long-term deal and near-term fundraising.
What to Expect
~₹3,700–3,850 Cr
Q1 FY27 was ₹2,627 Cr (+41% YoY); Q2 expected to maintain momentum on Zone IV ramp and energy segment strength
~14–15%
Q1 achieved 14.7% (₹385 Cr). Focus on continued operational leverage and cost optimisation as capacity utilisation improves
₹170–200 Cr
Dependent on tax charge; Q1 benefited from exceptional tax relief (₹29 Cr credit). Normalisation expected but not guaranteed
Volume growth + pricing
Energy segment momentum, specialty chemicals demand, and Phase I Zone IV contribution in Jul–Sep
A strong Q2 would show: revenue at or above ₹3,800 Cr (maintaining +35% YoY growth), EBITDA above ₹550 Cr (15%+ margin), and detailed commentary on Phase I Zone IV utilisation rates and ramp timing. Management guidance on FY28 EBITDA target (₹1,800–2,200 Cr, as stated in H1 FY26) with confidence that the capex cycle is yielding returns.
A weak Q2 would signal: revenue below ₹3,600 Cr (deceleration to <25% YoY), EBITDA margin compression below 13.5%, or cautious commentary on Phase I ramp timing or raw material cost inflation. Any miss on energy segment volume or demand headwinds in specialty chemicals would be key flags.
On Track?
Aarti is executing well on its FY27–28 capacity expansion plan. Q1 FY27 delivered 41% revenue growth and 79% EBITDA growth, a step-up from Q2 FY26's 26% / 44% trajectory. The Sep 2026 commissioning of Phase I Zone IV—including Calcium Chloride, PEDA, and Multipurpose facilities—should sustain momentum into Q2 and beyond. The company's medium-term guidance targets EBITDA of ₹1,800–2,200 Cr by FY28; at the current pace, this is on plan. However, the size of the ₹1,500 Cr long-term deal (announced Oct 13) and near-term fundraising of ₹1,000 Cr (announced Oct 1) suggest the board is gearing for accelerated capex and market opportunity capture. Q2 Q&A will be critical for timeline clarity on these deployments.
What the Street Says
Since Last Quarter
1 · ₹1,500 Cr Long-Term Deal (Oct 13)
Aarti signed a 10+ year strategic manufacturing and supply agreement with a global specialty chemical company. Revenue potential is material and suggests the company is winning share in global specialty chem supply chains. Phased implementation details are key to watch: ramp timing will determine whether this contributes to FY27 or FY28+ earnings.
2 · ₹1,000 Cr Fundraising (Oct 1–7)
Board approved raising up to ₹1,000 Cr via equity/convertibles/debt. EGM scheduled for Oct 31 to seek shareholder approval. This capital is clearly earmarked for capex or strategic M&A. Management commentary on deployment timeline will be closely watched.
3 · Phase I Zone IV Commissioned (Sep 7)
Includes Calcium Chloride, PEDA, and Multipurpose facilities in Jhagadia. Q2 results should provide first quantitative colour on utilisation rates and margin benefit. This is the near-term operational lever.
4 · Leadership Transition (Oct 1 effective)
Suyog Kotecha promoted to Managing Director & CEO (subject to shareholder approval). Routine governance update; no immediate operational impact flagged.
5 · Subsidiary in China (Jul 30)
Board approved incorporation of wholly owned subsidiary. Strategic, long-term play; no immediate earnings impact expected.
6 · Promoter Reclassification (Aug 3 & Oct 7)
Mrs. Ratanben Premji Gogri reclassified from Promoter Group to Public. No operational impact; routine governance. Promoter stake remains stable at ~42%.
The Setup
Aarti Industries enters Q2 FY27 on strong footing. Q1 delivered exceptional growth (41% revenue, 79% EBITDA growth), and the commissioning of Phase I Zone IV in Sep 2026 provides a tangible operational lever for Q2 onwards. The ₹1,500 Cr 10+ year contract win is a strategic milestone, though implementation timing is unclear. Street consensus is bullish on long-term earnings potential, but valuations at the 23.5% upside to ₹529.50 target embeds execution risk—particularly on how quickly the new deal and capex translate to P&L. Management's quarterly commentary on Phase I ramp utilisation, guidance on the ₹1,000 Cr fundraise deployment, and confirmation of the FY27–28 trajectory will be the focus.
Three Things to Watch on Oct 30
1 · Phase I Zone IV Utilisation & Margin Lift
How much of the 3-month ramp (Jul–Sep) is reflected in Q2 EBITDA? Management should quantify utilisation rates and guide on Q3–Q4 trajectory. This directly impacts FY27–28 guidance credibility.
2 · Energy Segment Momentum & Repricing
Energy drove Q1's outsized growth (+118% YoY, +48% QoQ). Is this sustaining into Q2, or normalising? Are raw material cost trends still easing, or are they creeping back in? Margin commentary here is critical.
3 · Fundraise & Capex Runway Visibility
Details on the ₹1,000 Cr fundraise timeline, end use (Zone V / Zone VI expansion, or the ₹1,500 Cr deal capex?), and how it shapes the FY28 EBITDA target (₹1,800–2,200 Cr) will reset investor confidence on the sustainability of this growth arc.
Aarti Industries is at an inflection point—Phase I Zone IV is live, a landmark long-term contract is signed, and capital is flowing in. Q2 will be the first true test of operational integration and the board's ability to articulate a clear path to FY28 EBITDA guidance. Street consensus is constructive, but the stock's 26.5% climb from the 52-week low and still-below-SMA positioning suggests the market is pricing in both upside optionality and execution risk. Expect detailed modelling focus on Phase I utilisation and the ₹1,500 Cr deal's revenue phasing—those will drive post-result re-ratings.
Informational and educational content only. Not investment advice.